Husain, Muhammad Ishrat
Cullen, Clare
Umer, Madeha
Carvalho, Andre F.
Kloiber, Stefan
Meyer, Jeffrey H.
Ortiz, Abigail
Knyahnytska, Yuliya
Husain, M. Omair
Giddens, Justine
Diniz, Breno S.
Wang, Wei
Young, Allan H.
Mulsant, Benoit H.
Daskalakis, Zafiris J.
Funding for this research was provided by:
Physicians' Services Incorporated Foundation
Article History
Received: 3 March 2020
Accepted: 17 March 2020
First Online: 15 April 2020
Ethics approval and consent to participate
: This study is approved by CAMH Research Ethics Board, Toronto (REB # 135/2018). Written informed consent is obtained from all participants prior to any study related activities.
: Not applicable.
: MIH is a PI for a trial sponsored by COMPASS Pathways Limited. MIH was previously a trustee of the Pakistan Institute of Learning and Living. MIH receives research support from the Brain and Behavior Research Foundation, the Physician’s Services Incorporated (PSI) Foundation and the University of Toronto. BSD receives research support from the NIH. BHM currently receives research support from Brain Canada, the Canadian Institutes of Health Research, the CAMH Foundation, the Patient-Centered Outcomes Research Institute (PCORI), the US National Institute of Health (NIH), Capital Solution Design LLC (software used in a study funded by CAMH Foundation), and HAPPYneuron (software used in a study founded by Brain Canada). Within the past five years he has also received research support (medications for NIH-funded clinical trials) from Bristol-Myers, Eli Lilly, and Pfizer. He directly own stocks of General Electric (less than $5,000). AHY has been commissioned to provide lectures and advice to all major pharmaceutical companies with drugs used in affective and related disorders. AHY has undertaken investigator-initiated studies funded by Astra Zeneca, Eli Lilly, Lundbeck and Wyeth.